Shield Therapeutics plc (FRA:1JS)

Market Cap	118.03M +258.9%
Revenue (ttm)	35.33M +93.2%
Net Income	-18.09M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	3,237
Open	0.1020
Previous Close	0.1050
Day's Range	0.1020 - 0.1020
52-Week Range	0.0225 - 0.1470
Beta	n/a
RSI	45.67
Earnings Date	Apr 24, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 63
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1JS

Financial Performance

In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.

Financial numbers in USD